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Abstract 
This paper presents the proceedings of the 5th Annual Meeting of the African Society of 
Human Genetics, which took place in Cairo, Egypt, on 3rd-5th November 2007.  The meeting 
provided a much needed forum for the development of research networks and collaborations 
for all who are interested in the field of ‘genetics in Africa’ in its broadest sense.  The 
meeting also presented an opportunity for the Society to debate the major issues in the field 
and to develop a long term strategy towards achieving the goals of the Society.  The most 
exciting and ambitious outcome of the meeting was the launch of the African Genome 
Project.  The meeting was held in conjunction with the First Annual Meeting of the Division of 
Human Genetics and Genome Research and the National Society of Human Genetics of 
Egypt. The conference theme was ‘Genomics Research in Africa: Implications for Disease 
Diagnosis, Treatment and Drug Development’.  Over 200 participants (including clinicians, 
geneticists, statisticians, bioinformaticians and social scientists) attended from 28 countries, 
16 of which are in Africa.     
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Introduction 
The African Society of Human Genetics (AfSHG) was established in 2003 to ‘equip the 
African scientific community and policymakers with the information and practical knowledge 
they need to contribute to the field of genetics research and to attract global attention to the 
efforts of African scientists’ [1].  The Society’s goal is to build the capacity of African 
researchers and institutions and create an infrastructure that can support and sustain that 
capacity. AfSHG aims to provide a platform on which the wealth of information and research 
opportunities accumulating from genomic and genetics research can be discussed.  AfSHG 
also aims to support the exploration of modern research methods and suggest ways in which 
these methods can be adapted to the special conditions in Africa.  This is essential if the 
widening gap between Africa and the Western world in biomedical science is to be 
addressed and access to scientific power for developing relevant resources in Africa is 
realised.  The Society provides a forum for scientists interested in Human Genetics in Africa 
in its broadest sense to meet, interact, network and collaborate.  This goal has been 
achieved through a series of annual workshops and meetings that have been held in four 
different African countries to date.  These activities are further advanced through its website 
(www.afshg.org), where a wide range of web based resources are under development. 
 
The 5th Annual Meeting of the AfSHG was held on 3rd-5th November 2007 at the National 
Research Centre (NRC), Cairo, in conjunction with the First Annual Meeting of the Division 
of Human Genetics and Genome Research and the National Society of Human Genetics of 
Egypt. The conference theme was ‘Genomics Research in Africa: Implications for Disease 
Diagnosis, Treatment and Drug Development’.  Over 200 participants attended from 28 
countries, 16 of which are in Africa – an increase from the 10 African countries represented 
in 2006 as new participants particularly from North African countries were welcomed.   
 
Opening session and keynote address: Africa and the Genomics Revolution 
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The opening keynote address (Africa and the Genome Revolution  was given by Professor 
Francis Collins, Director of the National Human Genome Research Institute, National 
Institutes of Health, USA.  Of his many achievements, perhaps the most notable was 
Professor Collins’ stewardship of the Human Genome Project (HGP).  Professor Collins is 
now focused on efforts to ensure the HGP output is translated into tools and strategies to 
advance biological knowledge and improve human health.  Professor Collins began with an 
overview of the achievements of the HGP and went on to outline important areas in which 
advances in genomics were likely to have benefits for human health.  Although the main 
focus of his talk was the human genome, the audience was reminded that much progress 
has also been made in deciphering the genomic sequences of major pathogens and vectors 
that are responsible for millions of deaths each year, especially in African countries.   
 
Our understanding of the genetics of common diseases has advanced rapidly since the 
availability of the human genome content and the International HapMap project which has 
provided a map of single nucleotide polymorphisms (SNPs) as well as information on linkage 
disequilibrium across the genome.  In 2002 the genetic basis of approximately 1600 
Mendelian disorders had been established, yet only seven complex trait genes had been 
identified [2].  The HapMap project (including the recently published phase II) [3] coupled 
with the technological developments it drove, has allowed genome wide association studies 
to become practical and affordable.  This has led to an exponential discovery of genetic 
variants associated with common diseases in the last few years.   
 
Specific applications of the human genome information were described.  The Cancer 
Genome Atlas is a collaboration between the National Human Genome Research Institute 
and the National Cancer Institute which aims to apply genome analysis technologies to 
accelerate our understanding of the molecular basis of cancer.  The HGP has also 
empowered much needed new drug discovery for neglected diseases that afflict millions of 
people living in resource-poor environments.  Professor Collins closed by considering the 
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future of genome research in Africa.  He highlighted the unique resources available – the 
great genetic diversity of African populations and their unique health problems, coupled with 
talent and creativity – and underlined the need for collaboration across the continent.  He 
concluded that whilst the science of genomics is new, in the long run its implications for 
healthcare in Africa are highly significant. 
 
Understanding genetic diseases in Africa: implications for research and public health 
strategies 
Professor Dominic Kwiatkowski (UK) explained how genetic networks such as MalariaGEN 
(http://www.malariagen.net/) could be used to unravel factors contributing to the causes and 
prevention of severe malaria.  He emphasized how collaborative effort was essential to 
achieve the objectives of MalariaGEN, which will require collection of DNA samples from 
more than 10,000 children with severe malaria. He also talked about issues surrounding the 
management and release of large volumes of genetic data, and mentioned the fellowship 
program in data analysis which is an important part of the network. 
 
Professor Charles Rotimi (USA) highlighted the importance of large scale collaborations as 
he used the example of the African American Diabetes Mellitus study (AADM) [4] to update 
the audience on the effect that new technologies are having on our ability to study complex 
diseases. He stressed the limitations posed by the current way most environmental data are 
gathered, and the public health issues raised by screening affected families in situations 
where medication availability is not guaranteed. However, the overall picture he delivered 
was very positive in terms of the progress of the three phases of AADM. So far, this ongoing 
genetic epidemiology project has enrolled and examined over 3,500 persons with type 2 
diabetes and controls from four major ethnic groups in Ghana (Akan and Gaa) and Nigeria 
(Ibo and Yoruba).    
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Professor Raj Ramesar (South Africa) presented data gathered from many years of study of 
families susceptible to colon cancer. He demonstrated the benefits of genetic screening not 
just on more precise targeting of colonoscopic screening, but also on overall mortality. He 
gave a thoughtful community perspective on screening for colon cancer, illustrating the need 
to move screening out to the community, and to study which factors affect uptake of 
information and attendance for screening. 
 
The experience of the African Diaspora was used by Dr Adebowale Adeyemo to discuss 
different approaches (genome wide scans, candidate gene studies, and others) to the 
genetics of hypertension. He summarized the candidate gene approach, pointing out the 
many inconsistencies that have arisen to date, the lack of replication and the problems of 
associations being found with intermediate phenotypes but not with hypertension itself. He 
described a couple of studies that used the admixture mapping approach, noting the utility of 
such study designs in populations such as African Americans. He noted a lack of African 
studies in meta-analyses of genome-wide scans for hypertension. He concluded by 
highlighting the need for more studies of the genetics of hypertension in African populations 
and for inclusion of African populations in genome wide association studies. 
 
Dr Donald Coppock (USA) and Professor Duncan Ngare (Kenya) talked about practical 
issues relating to setting up International HapMap Repositories. Dr Coppock concentrated 
on quality and safety issues at the Coriell Repository, and the importance of regular 
feedback to participating communities through newsletters. Professor Ngare focused on 
issues of information and consent that had arisen during data collection among the Masaai 
population in Kenya. 
 
Understanding the genetic basis of common diseases 
Professor Samia Temtamy (Egypt) gave an overview of the genetics of limb and skeletal 
malformations, one of the most important causes of disability in Egypt (prevalence rate of 
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1.7/1000).  She concluded that with the recent advances in molecular medicine it is 
becoming mandatory to apply these techniques in order to facilitate better understanding of 
the pathogenesis and genetics of these conditions.  Professors Riad Bayoumi and 
Mohammed Hassan (Oman) described their efforts to identify loci underlying 
obesity/diabetes and hypertension respectively in the ‘Oman Family Study’.  Five large 
extended consanguineous Arab families comprising 1280 persons have been phenotyped in 
great detail and genome wide linkage studies conducted in order to identify genes linked to 
various metabolic phenotypes.  A number of novel loci detected through these studies are 
under further investigation. 
 
Human genetic variation and disease 
An update on ‘Human polymorphisms and malaria selection’ by Professor Lucio Luzzatto 
(Italy) combined clinical work with recent molecular advances in malaria.  His talk started by 
reminding the audience of the role of natural selection in shaping genomes in their response 
to changes in the environment.  He then reviewed the pathogenesis of malaria disease, 
describing the intimate relationship between the parasite and host in the pathophysiology of 
malaria.  There have been different types of genetic adaptations in malaria: (1) those that 
affect the intracellular parasite in the vertebrate host, (2) powerful selection in one 
generation, and (3) consistent selection over some 300 years. Several genes in the human 
host have been implicated in resistance or susceptibility to malaria (α-globin, β-globin, 
spectrin, erythrocyte band 3, glycophorin C, G6PD, HLA-B, HLA-DBR1, TNF, CD36, ABO 
blood groups, Duffy chemokine receptor, ICAM-1, Complement receptor-1).   
 
Professor Luzzatto discussed the epidemiology of α- & β-globin polymorphisms, focusing on 
the β-globin-S (sickle) polymorphism, haemoglobin C, and then the role of glucose-6-
phospate dehydrogenase (G6PD) deficiency in malaria.  According to Professor Luzzatto, 
malaria is a tale of three genomes: (1) adaptive changes in the parasite, (2) adaptive 
changes in the vector and (3) adaptive changes in the human. His presentation 
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contextualized these components and highlighted how the effects of selection and genetic 
drift influenced population dynamics.  
 
Dr Floyd Reed (USA), spoke on the genetic basis of human adaptation in Africa and its 
implications for human evolution and human disease.  Numerous microsatellite and 
insertion-deletion polymorphisms were genotyped in 84 African ethnic groups, as well as 
samples drawn from African American, Yemeni, Indian, Caucasian, and Australian 
populations, and patterns of variation analyzed using the STRUCTURE program.  There was 
evidence for partitioning of the data between African and non-African populations, and as 
the numbers of cluster groups increased, there was a concomitant partitioning within the 
African region showing that the populations presently in residence in West, East, North, 
Central and Southern Africa harbor very distinctive collective patterns of variation.   
However, while the program STRUCTURE was good at dividing individuals into clusters that 
represented recent population structure, it could not directly provide information on the 
evolutionary history of the populations.  The isolation with migration method [5] was thus 
used to jointly infer the amount of migration and time of common ancestry between pairs of 
populations.  Interestingly, Southern Africa showed the highest amount of genetic structure 
(layers of different patterns of variation) followed by the Middle Eastern Area and then East 
Africa. 
 
Dr Sylvester Kajuna (Tanzania) spoke on ‘Genetic diversity within Africa based on 
autosomal haplotypes’.  The objective of this research was to establish a large set of 
markers on African populations that could serve three purposes: (1) determine the genetic 
relationships of African populations in the global context, (2) serve as a reference set of 
markers for future studies, and (3) examine the value of haplotypes for defining and 
understanding the relationships among African populations and the effects of “Out of Africa” 
founder effects.  The sample of African populations consisted of Biaka from Central African 
Republic; Mbuti from the Democratic Republic of Congo; Yoruba, Ibo and Hausa from 
  10 
Nigeria; and Masai, Chagga and Sandawe from Tanzania. Other populations sampled 
included Ethiopian Jews, African Americans, SW Asians/Europeans, and San , Mandenka, 
Bantu-speakers and Mozabites from the HGDP-CEPH sample collection.  Analysis of 
haplotype data for two genes (BRCA1 and SLC6A4) showed higher genetic variation being 
found among African populations compared with those outside of Africa – an observation 
that has been supported by many other studies.   
 
Understanding the human journey within and outside Africa 
Continuing on the theme of human population variation in Africa, Dr Himla Soodyall’s (South 
Africa) talk entitled “Understanding human migration: the Genographic Project” focused on 
how mtDNA and Y chromosome DNA variation can be used to map patterns of genetic 
variation within sub-Saharan Africa.  The Genographic Project was launched in 2005 as a 
multi-dimensional initiative with three major activities: (1) a global DNA sampling aimed at 
collecting approximately 100,000 samples from indigenous populations around the world, 
and to use these samples for anthropological research in an attempt to answer fundamental 
questions about humankind’s origins and migrations, (2) a public participation component 
through which members of the public could purchase cheek swab kits to trace their 
ancestries, and (3) an educational legacy project that will benefit communities and peoples 
participating in the research.   
 
Dr Soodyall presented her research under three themes.  Firstly, she discussed the use of 
autosomal DNA SNPs in examining the genetic structure and affinities of San, Khoe and 
Bantu-speaking groups in southern Africa. Using the programme STRUCTURE it was clear 
that the San and Khoe shared a common genetic background and this background of 
genetic variation ranged in frequency (25-90%) among the different San and Khoe groups 
examined.  Secondly, she discussed how trade activities in the wider Indian Ocean Rim 
have influenced the gene pools of African (Zanzibar) and Malagasy populations. 
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Approximately 95% of mtDNA types found in Zanzibar was traced to origins in Africa with the 
remaining 5% tracing to non-African sources, predominantly Asian. However, when Y 
chromosome DNA markers were used about 20% of Y chromosome could be traced to non-
African geographic regions of origin, especially from the Middle East.  Thirdly, she reported 
that mtDNA and Y chromosome DNA signatures found among African populations may still 
harbor vital clues concerning the geographic region of origin of modern humans. Some of 
the oldest surviving mtDNA and Y chromosome DNA lineages are found among people who 
presently self-identified as San and Khoe.  
 
Dr Emily Neimitz (Nature Genetics, USA) closed this session with a stimulating discussion of 
regional populations and the increasingly flat world of genetics.  Her title was inspired by a 
book, ‘The world is flat’, written by Thomas L Freidman which explores how new 
technologies have circumvented traditional obstacles to development as people ‘plug, play, 
compete, connect and collaborate with more equal power than ever before’[6].   
 
Genetics and genomics of cancer 
Professor Sir Walter Bodmer introduced the main concept underpinning the molecular basis 
of cancer - that cancer is a somatic evolutionary process in which successive genetic 
mutations or changes in gene expression are selected for.  The challenge is to identify these 
changes, to establish their functional basis and to find ways to use the information for early 
detection and the development of new drugs.  Professor Bodmer illustrated this concept 
using genes involved in colorectal cancer (CRC).  Although predisposition to CRC is 
inherited as a dominant trait, germline mutations only contribute to cancer development if 
there is a second somatic event leading to the loss of the single wild type allele.  Mutations 
in genes encoding components of the Wnt pathway, cell cycle check points, growth factor 
signalling receptors, apoptosis and the immune system have all been associated with CRC 
and selection for mutations in different pathways will occur at different stages of the 
transition from adenoma to carcinoma.   
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Professor Bodmer also discussed the impact of carcinogenic mutations at the population 
level, addressing the ‘common alleles versus rare variants’ hypothesis postulated for 
common multifactorial diseases.  In the former, disease association is detected as a result of 
linkage disequilibrium with a common allele and the odds ratios are generally small.  In the 
latter, rare variants, each with a moderate effect, in a number of genes cumulatively have a 
larger and more readily detectable effect.  Professor Bodmer elegantly addressed this 
dichotomy using data generated from patients with multiple adenomatous polyps (MAP) who 
were screened for germline variants in genes involved in wnt signalling (APC, Axin1 and 
CTNNB1) and mismatch repair (hMLH1 and hMSH2) on the assumption that such variants 
could give rise to inherited susceptibility to colorectal adenomas.  483 healthy population 
controls were then screened for any DNA variants identified in the MAP patients.  These 
variants were twice as common in the MAP cases compared to controls, and the majority 
were functional.  The odds ratios associated with the variants were high, yet the low 
frequency of the individual variants precludes them from being useful in classic cases control 
studies.  In contrast, common alleles found to be associated with disease in case control 
studies have lower odds ratios and since they are in linkage disequilibrium with the causative 
variant, ascertaining function is difficult.  A review of published data showed a clear 
reciprocal pattern between odds ratio for rare versus common variants.  Reviewing data for 
BRCA2 and breast cancer he concluded that collectively, rare variants make a substantially 
greater contribution to genetic susceptibility at loci such as BRCA1, 2 and APC than the total 
of frankly deleterious familial mutations.  Taken together, these analyses have important 
strategic implications for scientists aiming to identify disease genes – the currently 
fashionable genome wide association studies that use common SNPs to detect association 
will miss the important rare causative variants that can only be detected through sequencing 
of candidate genes in carefully selected patients.   
 
Dr Hassan Ashktorab (USA) described studies of sporadic colorectal cancers for expression 
and methylation status of mismatch repair genes known to be involved in colorectal cancer 
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and other epigenetic phenomena such as global acetylation of histone 3 and 4 and HDAC2, 
and microsatellite instability.  Genome wide approaches including comparative genome 
hybridization were also employed.  A number of genetic and epigenetic changes in sporadic 
colorectal cancers in African Americans were identified and it was postulated that an 
integrative approach could help identify pathways involved in colorectal carcinogenesis.   
 
Dr Renato Mariani-Costantini (Italy) presented his studies on breast cancer in Central 
Sudan, a disease that to date has been relatively neglected in Sub-Saharan Africa.  BRCA1, 
BRCA2 and p53, the three main genes associated with breast cancer, were studied in young 
women presenting with breast cancer in Sudan.  Through sequencing, a number of variants 
were identified in these genes, many of which were unique to the population.  A subset of 
these mutations were pathological and comparison with Italian cases demonstrated that 
Sudanese cases tended to be younger, with more advanced, more aggressive disease that 
was more likely to be estrogen receptor positive in immunohistochemical staining than the 
Italian cases.   
 
Professor Lofti Chouchane (Qatar) discussed the preventative and predictive medicine 
implications of the advances in the genomics of cancer.  Professor Chouchane discussed 
the known germline mutations in genes such as BRCA1 and 2 that are responsible for 
familial forms of breast cancer.  However, there are differences in patterns of disease 
between populations that involve other genetic factors as well as socioeconomic factors.  
Professor Chouchane highlighted the role of immune response genes in the development of 
breast cancers, with polymorphisms in pro-inflammatory genes such as interleukins 1 and 6 
and tumour necrosis factor being associated with a worse prognosis for some women.   
 
Dr Wael El-Rifae (USA) gave a concise overview of how functional integrated ‘Omics’ can 
contribute to our understanding of malignant disease.   His laboratory has taken a lead in the 
molecular characterization of upper gastrointestinal adenocarcinomas (UGC) and in making 
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use of the ‘omic’ information from genomics, epigenomics, transcriptomics, and proteomics 
to better understand the cancer genome as well as the possible clinical and therapeutic 
impact of the findings. Comparative genomic hybridization analysis revealed a complex 
pattern of DNA losses and amplifications. The group has mapped the genomic and 
transcriptomic molecular alterations and developed an anatomical view of these genetic 
changes along the human genome. Clusters of transcriptional oncogenomic hotspots were 
identified and classification of genes into functional sets according to their biological and 
molecular activity revealed alterations of cellular pathways including cell cycle regulation, 
adhesion, apoptosis, and invasion.  Some of the most clinically relevant findings of this 
integrated approach are the detection of alterations in several genes that are candidate 
therapeutic targets for UGCs.  
 
Genomic technologies, pharmacogenomics and bioinformatics 
Dr Farideh Chitsaz (USA) gave an educational overview of the facilities available to identify 
disease causing genes in silico, through genomic sequence data mining.  Online resources 
are expanding and the facilities available though the National Center for Biotechnology 
Information were described.  Professor Giuseppe Novelli (Italy) spoke about genomic 
biomarkers in pharmacogenetics and pharmacogenomics, using large clinical intervention 
trials for cardiovascular disease as his starting point.  Whilst many patients benefit from such 
interventions, others do not and some have serious adverse reactions to the intervention.  
There is undoubtedly a genetic contribution to such responses and further studies are 
required to unravel which genes are involved and how they interact with environmental 
factors.  One of the roles of the AfSHG is to promote networking, training and collaboration 
within the African continent.  Bioinformatics lends itself well to this model as it does not 
require expensive technology and reagents and there are well established centres of 
excellence.  Dr Daniel Jacobson, of the National Bioinformatics Network, South Africa, 
described a model for bioinformatics networks in Africa based on the system being 
pioneered in South Africa.  Dr Pasquale De Blasio (Italy) spoke in the topic of biorepositories 
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in Africa.  These are key resources in the days of genome and proteome based research, 
and whilst the advantages of setting up large collections of biological material may be 
obvious, there are a number of problems that need to be overcome.   
 
Tomorrow’s technologies 
Dr David Bentley (Illumina Inc) played a leading role in the human genome sequencing 
project as well as the SNP Consortium and the International HapMap Project.  He has been 
at the forefront of development of new DNA sequencing technologies and the subject of his 
talk at this meeting was “New sequencing technology and changing horizons”.  As well as 
describing the new technologies, Dr Bentley explained the applications of such advances.  
Whilst the human genome project was a major scientific landmark, cheaper, faster methods 
are required to enable wider application of genomic advances, for example to allow 
discovery of genetic variation underpinning disease and enhanced understanding of the 
biological implications (and therefore potential therapeutic interventions) of this variation.  Dr 
Bentley also illustrated how such advances can be applied to other organisms, focusing in 
his talk on Mycobacterium tuberculosis, one of the leading infectious killers of humans.   
 
Tomorrow’s medicine 
Dr Griffin Rodgers, Director of the National Institute of Diabetes, Digestive and Kidney 
Diseases, NIH, USA, and internationally recognised for his research towards the 
development of new therapies for sickle cell disease (SCD) spoke on ‘Stem cell therapy for 
sickle cell disease: transplantation and gene therapy’.  Dr Rodgers reviewed the molecular 
pathophysiology underlying the chronic haemolysis and microinfarction that characterises 
SCD.  It is recognised that although all patients with SCD are homozygous for the same 
mutation, there is huge variation in the clinical phenotype and the factors that modify the 
disease phenotype include the genetic haplotype in which the sickle mutation is embedded, 
other genetics factors, local cellular and physiological factors and psychosocial factors.  He 
went on to describe the discovery of hydroxyurea as a successful new therapy for SCD, 
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acting through increasing the level of fetal haemoglobin, but noted that this did not work for 
all patients.  This observation drove research on stem cell therapies aimed at replacing the 
defective erythrocyte population.  Traditional ablative methods of stem cell transplantation 
are being superceded by less intensive (non-myeloablative) stem cell transplantation which 
is now being assessed in carefully selected patients. 
 
Dr Alice Abdel-Aleem (Egypt) described her studies on the differentiation of neuroprogenitor 
cells derived from human embryonic stem cells into various neuronal cell types, focusing 
especially on the technical challenges of this work, bringing together scientists from the 
fields of molecular biology, molecular genetics, biomaterials and laser technology.  Dr Tarek 
Badry (Egypt) described the application of stem cell technology to the development of new 
therapies for reconstruction of tissues and bone in vivo using dental pulp stem cells and 
periodontal ligament stem cells.  These cells have a number of stem cell-like properties and 
their easy accessibility is an added advantage. 
 
Free papers 
Two sessions of the meeting were dedicated to free oral papers selected from submitted 
abstracts.  A wide variety of topics from a number of studies based in different locations 
across Africa were covered, including:  
Population genetics (Hisham Hassan, Sudan; Iliena Pietrangeli, Italy/Benin/Mongolia), 
cytogenetic techniques (Ashraf Ibrahim, Egypt), gene expression (Yousif Idaghdour, 
USA/Morocco), vaccine response genetics (Dr Branwen Hennig, UK/Gambia), systematic 
reviews (Mark Engel, South Africa), molecular diagnosis and genetic counselling especially 
regarding congenital disorders (Katherine Balk, USA/Mali; Wafa Cherif, Tunisia; Wafa 
Troudi, Tunisia; Dr Ambroise Wonkam, Cameroon), comparative genomics (Dr Mohamed 
Aboueldhouda, Germany/Egypt), ethical issues (Professor Gail Davey, Ethiopia) and 
database establishment (Dr Ghada Abdel-Salam, Egypt). 
 
  17 
The work presented gave a good overview of the breadth of research going on across the 
continent at present. It also gave a snapshot of the background and setting for many studies, 
whether studies were carried out fully in Africa or in collaboration with others outside of 
Africa. For instance, international collaborations give opportunity to some scientists to 
access large-scale facilities (still lacking in most parts of Africa) whilst simultaneously, 
researchers in the field of human genetics in Africa are shifting from simply providing 
samples to building and strengthening local capacities to investigate genetic diseases, 
particularly for hereditary monogenic diseases, which is of great importance in tackling the 
"genomic" divide.  A total of 55 posters selected from submitted abstracts were also 
presented over the course of this meeting. 
 
AfSHG Young Investigator Prize 
The Young Investigator Prize was launched at this AfSHG meeting with the aim to promote 
young researchers in the field of genetics in African populations or those of African ancestry.  
A panel consisting of five judges was appointed to nominate the three best oral 
presentations.  There were 11 entries for the best oral and 53 for the best poster 
presentations, from researchers based in 21 different countries. We are grateful to all 
sponsors who supported this Prize competition, through which the winners have gained 
online subscriptions to scientific journals or received text books that are often not accessible 
for those based in African countries, or were given sponsorship to attend the next annual 
meeting of the AfSHG.  
 
Developing an African Genome Project to ensure that tomorrow’s medicine and 
technology will work for all humans 
 
The potential benefits of the ongoing Human Genome Project and similar genomic research 
are enormous and may form the basis of many breakthroughs in biomedical technology and 
healthcare.  Furthermore, the continent of Africa has a significant attachment to the human 
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genome and may hold the key to our understanding of its current form and how it may 
change in the future.  This understanding may shed light on the best ways to manipulate 
information about the human genome and other genomes for the benefit of individuals and 
society.  Given its objectives, the AfSHG is well –placed to lead the development of an 
exciting, ambitious new initiative: the African Genome Project (AGP), and a consultation with 
the wider membership took place during the 5th AfSHG meeting.  This consultation allowed 
leading African and international scientists to discuss the opportunities and challenges of 
developing this major African biomedical project that will support large-scale population 
based application of recent genomics tools to gain novel insight into the determinants of both 
communicable and non-communicable diseases important to Africa populations.   
 
A major rationale for the establishment and design of an AGP was the concern that the 
equity gap that already exists between developed and developing countries will be widened 
if developing country populations, their scientists and health practitioners are not fully 
engaged in the application of genomic tools to address global problems including health and 
food production.  It was also widely expressed that global inequality in health will be 
exacerbated if we do not ensure that “Tomorrow’s Medicine and Technology” will work for all 
humans and that Africa will not be left out of the genomic revolution.  
 
The AGP will define the critical research priorities required to improve health for all Africans, 
and the study designs required to tackle them through capturing the genetic diversity within 
the continent and subsequent application to disease.  The AGP will foster partnerships that 
enhance capacity building and infrastructure development through strengthening of local 
expertise at the level of the continent, rather than country or institutional level.   
 
The AGP project will have four major components: population genetics, medical genetics, 
training and infrastructure development. The population genetics component of AGP will 
facilitate a more comprehensive understanding of genetic diversity in African people by 
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conducting a systematic sampling a minimum of 100 ethnic groups across the continent 
(North, East, West, Central and South). The medical genetics aspect of AGP will facilitate 
the development of large-scale population based resources to understand the genetic and 
environmental determinants of diseases important to African people and the global 
community. The third component of the AGP will facilitate the training and participation of 
African scientists in the global effort to use genomic tools to solve global health problems. 
Successful implementation of the first three components of the AGP will require the 
development and implementation of appropriate infrastructure in strategic locations in the 
continent.  
 
When the burden of disease is analyzed, it is clear where the research priorities lie: for 
example, HIV, malaria and TB claim millions of lives, and the increasing prevalence of non-
communicable diseases such as hypertension, diabetes and mental health disorders is 
contributing hugely to changing disease demographics in Africa.  However, whilst the health 
priorities may appear to be obvious, many questions remain that will inform and shape the 
development of the AGP: exactly who should we study; who are the stakeholders; how do 
we ensure engagement of African populations and their leaders for full support for the 
project? 
   
Careful assessment of existing infrastructure within Africa is needed as is the identification 
and/or establishment of regional infrastructure that will support sample collection, processing 
and storage.  Development of regional genomics laboratories in Africa is required to facilitate 
the engagement and training of African scientists and students in genomic research.   
 
Ethical considerations in the implementation of an African Genome Project 
There are several complex ethical, cultural, social and potentially legal issues to consider 
around the implementation of the AGP.  It is likely that these issues can be satisfactorily 
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addressed by careful engagement of African communities, design and interpretation of study 
results.  Three key components of the proposed project have been identified: Governance, 
Research, and Translation, and these need to be considered in conjunction with the three 
supporting and areas of education and training, community engagement, and capacity 
building.   
 
Questions regarding Governance include: In which country or countries will the project be 
based?  Who will have oversight of the resource?  Where will the resource be housed?  How 
will decision-making take place regarding the project?  What are the potential funding 
mechanisms for such a project?  Clearly, issues of representation, equity, and control and 
power would be crucial to future deliberations and resolution about leadership of the project.   
 
With regard to Research, there are concerns about genetic variation research and its 
implications for African communities, in particular, around the potential for reification of 
existing notions of difference and/or the creation of new opportunities for stigmatization, 
discrimination, and conflict.  There was unanimous agreement by the AfSHG membership 
that this is a valid concern that requires substantial attention and that must be carefully 
balanced with the potential benefit of the project to Africa and the global community.  Some 
meeting participants also expressed fear that African investigators would not have equal 
access to the resource, ample opportunity to lead or collaborate on research projects, or 
receive adequate recognition (eg. authorship on publications) for their contributions to 
projects.  These discussions served to highlight the exceptional role of the supporting 
elements (education/training, community engagement, and capacity building) in all aspects 
of the development of the resource and implementation of related research.  
 
Regarding issues associated with Translation and the practical or clinical application of the 
research, there are questions concerning access of Africans to diagnostics, treatments, and 
preventive measures emanating from the research.  The establishment of strategic 
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partnerships with biotechnology and pharmaceutical may be required to address this issue.  
A need was identified for deliberate attention to education and training for genetic 
counsellors and other genetics professionals who would interpret and communicate clinical 
genetics findings, as well as for clinicians who would incorporate these genetic and genomic 
findings into their healthcare practices.  In addition, there was considerable discussion about 
potential personal, cultural, and social barriers to utilization of genome-related services 
among Africans.  This led to the acknowledgement of the dearth of available information on 
these issues within Africa, and underscored the need for additional research in this arena.   
 
Discussions at the annual meeting formed an extremely useful starting point for considering 
the potential ethical and social implications of a project of this magnitude.  As ideas about an 
AGP continue to develop, attention to these critical underlying issues will also evolve as we 
seek to ensure maximum benefit and minimum harm to African individuals, families, 
communities, and societies. 
 
In summary, the AGP is firmly on the agenda for the AfSHG and a special meeting to further 
develop the initiative, in which stakeholders and potential funding agencies will also 
participate, is planned for 2009 when the AfSHG next meets.   
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Young Investigator Prize winners and panel 
From left to right: Prof. Charles Rotimi (AfSHG president), Nejla Bel Hedi, 
Youssef Idaghour, Illenia Pietrangeli, Kathy Balk, Alice Matimba, Prof. Samia 
Temtamy (local committee, judge), Dr. Branwen Hennig (Prize coordinator), 
Yasmin Khalel, Prof. Sir Walter Bodmer (judge); not shown Ashraf Hosni 
Ibrahim, Amani A. Elamin and Shamman Sewram. 
